Seyed Mohammad Ghavam
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Seyed Mohammad Ghavam has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Ali Jahanshahi
Social Determinants of Health Research Center, Trauma Institute Guilan University of Medical Sciences Rasht Iran
1 shared publication - Hamid Harandi
School of Medicine Tehran University of Medical Sciences Tehran Iran
1 shared publication - Hanye Sohrabi
Tehran University of Medical Sciences
1 shared publication - Negin Frounchi
Kidney Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
1 shared publication - Nima Rezaei
Research Center for Immunodeficiencies, Pediatrics Center of Excellence, Children's Medical Center Tehran University of Medical Sciences Tehran Iran
1 shared publication - Sara Momtazmanesh
Department of Radiology and Radiologic Sciences, Johns Hopkins University, Baltimore, Md
1 shared publication
Latest Publications
- Open Access
- 17 February 2026
- Published by Wiley in Cancer Medicine
- Vol. 15 (2) , e71637
Efficacy and Safety of Combination Therapy With Immune Checkpoint Inhibitors and Chemotherapy With Gemcitabine and Nab‐Paclitaxel in Pancreatic Cancer: A Systematic Review
Background: Pancreatic cancer (PC) is a lethal malignancy with a 5‐year survival rate of 13% as the 7th leading cause of cancer‐related death worldwide. Most patients are ineligible for resection at diagnosis. Monotherapy with immune checkpoint inhibitors (ICIs) has shown limited success in PC, with objective response rates below 5% and median overall survival rarely exceeding 6 months. This systematic review evaluates the efficacy and safety of combining gemcitabine and nab‐paclitaxel with ICIs in pancreatic cancer. Objective: To assess the efficacy and safety of combining gemcitabine and nab‐paclitaxel chemotherapy with ICIs in patients with pancreatic cancer. Methods: A comprehensive search of PubMed, Scopus, and Web of Science was performed using predefined keywords. Eligible studies included original research articles employing interventional, cohort, case–control, or cross‐sectional designs. Case reports, case series, and review articles were excluded. Data extraction and quality assessment using the Mixed Methods Appraisal Tool (MMAT, 2018) were conducted independently by two reviewers. Results: Of 1904 search results, seven studies met inclusion criteria: four clinical trials and three retrospective cohorts. Sample sizes ranged from 17 to 180 participants with advanced or locally advanced PC. Median overall survival was ~15 months (range: 9.8–16.7) versus 8–9 months for chemotherapy alone. Progression‐free survival ranged from 5.5–9 versus 3.5–5.5 months. Objective response rates varied between 18%–50% for combination therapy and 23%–29% for chemotherapy. Grade 3–4 adverse events were mainly hematologic (anemia, neutropenia) and neurologic (fatigue, peripheral neuropathy). ICIs included PD‐1 inhibitors (pembrolizumab, nivolumab, toripalimab, camrelizumab, tislelizumab, sintilimab), PD‐L1 inhibitor (durvalumab), and CTLA‐4 inhibitor (tremelimumab). Conclusion: Combining ICIs with gemcitabine and nab‐paclitaxel appears feasible and safe, with signals of improved efficacy compared with chemotherapy alone. However, evidence remains limited, and further large‐scale trials are warranted to confirm survival benefits and optimize therapeutic strategies in pancreatic cancer.
- 17 February 2026
- Published by Wiley in Cancer Medicine
- Vol. 15 (2) , e71637
Open AccessEfficacy and Safety of Combination Therapy With Immune Checkpoint Inhibitors and Chemotherapy With Gemcitabine and Nab‐Paclitaxel in Pancreatic Cancer: A Systematic Review
Background: Pancreatic cancer (PC) is a lethal malignancy with a 5‐year survival rate of 13% as the 7th leading cause of cancer‐related death worldwide. Most patients are ineligible for resection at diagnosis. Monotherapy with immune checkpoint inhibitors (ICIs) has shown limited success in PC, with objective response rates below 5% and median overall survival rarely exceeding 6 months. This systematic review evaluates the efficacy and safety of combining gemcitabine and nab‐paclitaxel with ICIs in pancreatic cancer. Objective: To assess the efficacy and safety of combining gemcitabine and nab‐paclitaxel chemotherapy with ICIs in patients with pancreatic cancer. Methods: A comprehensive search of PubMed, Scopus, and Web of Science was performed using predefined keywords. Eligible studies included original research articles employing interventional, cohort, case–control, or cross‐sectional designs. Case reports, case series, and review articles were excluded. Data extraction and quality assessment using the Mixed Methods Appraisal Tool (MMAT, 2018) were conducted independently by two reviewers. Results: Of 1904 search results, seven studies met inclusion criteria: four clinical trials and three retrospective cohorts. Sample sizes ranged from 17 to 180 participants with advanced or locally advanced PC. Median overall survival was ~15 months (range: 9.8–16.7) versus 8–9 months for chemotherapy alone. Progression‐free survival ranged from 5.5–9 versus 3.5–5.5 months. Objective response rates varied between 18%–50% for combination therapy and 23%–29% for chemotherapy. Grade 3–4 adverse events were mainly hematologic (anemia, neutropenia) and neurologic (fatigue, peripheral neuropathy). ICIs included PD‐1 inhibitors (pembrolizumab, nivolumab, toripalimab, camrelizumab, tislelizumab, sintilimab), PD‐L1 inhibitor (durvalumab), and CTLA‐4 inhibitor (tremelimumab). Conclusion: Combining ICIs with gemcitabine and nab‐paclitaxel appears feasible and safe, with signals of improved efficacy compared with chemotherapy alone. However, evidence remains limited, and further large‐scale trials are warranted to confirm survival benefits and optimize therapeutic strategies in pancreatic cancer.
- 24 November 2025
- Published by Wiley in Journal of Clinical Ultrasound
- Vol. 54 (4) , 889-903
High‐Intensity Focused Ultrasound in Treatment of Primary Breast Cancer: A Systematic Review and Meta‐Analysis
Background: In recent years, tumor management strategies have focused on less invasive methods, aiming to yield optimal efficacy while minimizing further complications and enhancing the overall outcome of patients. High‐intensity focused ultrasound (HIFU), a known thermal ablative technique, has shown promising results in breast cancer treatment. Therefore, we performed this systematic review and meta‐analysis to assess the clinical, histopathologic, immunologic, and radiologic outcomes of HIFU ablative therapy and its complications in patients with primary breast cancer. Methods: We searched PubMed and Scopus databases to identify the eligible articles. Data extraction was conducted by two independent authors. A random effects model was employed to pool the proportion of remaining tumor after HIFU therapy in breast cancer. A subgroup analysis was performed according to imaging guidance modality and study design. Moreover, the heterogeneity and bias were assessed using funnel plot, Egger's regression plot, and Baujat plot. Pooled CD4/CD8 ratio mean difference between HIFU and radical mastectomy was measured using a fixed‐effect model. Results: We included 26 studies and 677 participants in the systematic review. Tumor necrosis rates varied, with 4 studies reporting less than 50% complete necrosis and 5 more than 50%. Two studies observed HIFU‐induced disturbances in the microvasculature of the targeted tissue. Six noted no contrast enhancement in successfully treated areas, two observed a thin rim indicating necrosis or fibrosis, and four reported a persistent enhancement in MRI images associated with a residual viable tumor. The weighted proportion of patients with residual tumor was 0.59 (95% CI; 0.44–0.73). The subgroup analysis demonstrated that although the pooled proportion of ultrasound‐guided studies was notably higher than magnetic resonance imaging‐guided studies (0.71 vs. 0.57), the between‐group difference was not statistically significant ( p = 0.1693). The diagnostic tools showed that the results are driven by certain studies, and there is also a potential small‐study effect. Furthermore, the CD4/CD8 ratio was higher in the HIFU group, with a weighted mean difference of 0.6 (95% CI: 0.41–0.78). The most prevalent side effects were pain (47.14%) and skin burn (2.59%). Conclusions: HIFU is a relatively safe procedure for the treatment of breast cancer as an independent or conjugated therapy and its effectiveness is promising regarding histopathological response, immunological reactivity, and vascular damage in the targeted area.
- 24 November 2025
- Published by Wiley in Journal of Clinical Ultrasound
- Vol. 54 (4) , 889-903
High‐Intensity Focused Ultrasound in Treatment of Primary Breast Cancer: A Systematic Review and Meta‐Analysis
Background: In recent years, tumor management strategies have focused on less invasive methods, aiming to yield optimal efficacy while minimizing further complications and enhancing the overall outcome of patients. High‐intensity focused ultrasound (HIFU), a known thermal ablative technique, has shown promising results in breast cancer treatment. Therefore, we performed this systematic review and meta‐analysis to assess the clinical, histopathologic, immunologic, and radiologic outcomes of HIFU ablative therapy and its complications in patients with primary breast cancer. Methods: We searched PubMed and Scopus databases to identify the eligible articles. Data extraction was conducted by two independent authors. A random effects model was employed to pool the proportion of remaining tumor after HIFU therapy in breast cancer. A subgroup analysis was performed according to imaging guidance modality and study design. Moreover, the heterogeneity and bias were assessed using funnel plot, Egger's regression plot, and Baujat plot. Pooled CD4/CD8 ratio mean difference between HIFU and radical mastectomy was measured using a fixed‐effect model. Results: We included 26 studies and 677 participants in the systematic review. Tumor necrosis rates varied, with 4 studies reporting less than 50% complete necrosis and 5 more than 50%. Two studies observed HIFU‐induced disturbances in the microvasculature of the targeted tissue. Six noted no contrast enhancement in successfully treated areas, two observed a thin rim indicating necrosis or fibrosis, and four reported a persistent enhancement in MRI images associated with a residual viable tumor. The weighted proportion of patients with residual tumor was 0.59 (95% CI; 0.44–0.73). The subgroup analysis demonstrated that although the pooled proportion of ultrasound‐guided studies was notably higher than magnetic resonance imaging‐guided studies (0.71 vs. 0.57), the between‐group difference was not statistically significant ( p = 0.1693). The diagnostic tools showed that the results are driven by certain studies, and there is also a potential small‐study effect. Furthermore, the CD4/CD8 ratio was higher in the HIFU group, with a weighted mean difference of 0.6 (95% CI: 0.41–0.78). The most prevalent side effects were pain (47.14%) and skin burn (2.59%). Conclusions: HIFU is a relatively safe procedure for the treatment of breast cancer as an independent or conjugated therapy and its effectiveness is promising regarding histopathological response, immunological reactivity, and vascular damage in the targeted area.